Clinical trial
Omacor and Cardiovascular Risk Factors in HIV Patients on HAART Treatment
NCT00296153 · Pronova BioPharma, Industry · Completed
Key facts
| NCT number | NCT00296153 |
|---|---|
| Title | Omacor and Cardiovascular Risk Factors in HIV Patients on HAART Treatment |
| Official title | Omacor; Omega-3-Acid Ethyl Ester 90 (n-3 PUFA) and Risk Factors in HIV Infected Patients Treated With HAART, With Special Focus on Lipids |
| Lead sponsor | Pronova BioPharma, Industry |
| Collaborators | Aalborg University Hospital |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Human Immunodeficiency Virus, Ischemic Heart Disease |
| Intervention type | Drug |
| Interventions | Omega-3-acid ethyl esters 90 |
| Enrollment | 51 |
| Start date | Feb 1, 2006 |
| Primary completion | Nov 1, 2006 |
| Completion | Oct 1, 2007 |
| First posted | Feb 24, 2006 |
| Last update posted | Mar 11, 2008 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: